#United States #Boston #NGS #DNAe #LiDia-SEQ

DNAe to Introduce Groundbreaking NGS-Based Diagnostic Platform at AMP 2025

In an exciting development for medical diagnostics, DNAe, a pioneer in Next-Generation Sequencing (NGS), is set to unveil new data from its innovative diagnostic platform at the Association for Molecular Pathology (AMP) Annual Meeting and Expo. Taking place in Boston, Massachusetts from November 11th to 15th, 2025, the conference will provide a platform for DNAe to showcase its LiDia-SEQ™ system, a fully automated sample-to-result diagnostic technology.

The LiDia-SEQ™ platform is distinguished as the first-ever system capable of automating the entire diagnostic process within a single device. This revolutionary technology significantly enhances the speed and accuracy of detecting bloodstream infections and identifies antimicrobial resistance (AMR) profiles directly from whole blood samples. Unlike traditional lab-based blood cultures that might take days for results, LiDia-SEQ™ offers near-patient testing capabilities, providing results within hours.

Samuel Reed, the CEO of DNAe, expressed enthusiasm for the upcoming presentation at AMP 2025, noting the strong interest in their latest datasets. “Our focus is now on finalizing our flagship BSI/AMR test, which can rapidly detect and identify life-threatening infections. This innovation brings critical insights to clinicians in urgent care situations,” said Reed.

Given the rising concerns around antimicrobial resistance and the dire need for rapid diagnostic tools, DNAe's technology is positioned to revolutionize how infectious diseases and cancers are detected and monitored. The company aims to provide actionable information that can help medical professionals make timely and informed decisions regarding patient care.

At AMP 2025, attendees can look forward to several poster presentations showcasing this breakthrough technology:

• - Direct Detection of Bloodstream Pathogens

- Date: November 14th, 2025, 9:15 AM - 10:15 AM EST
- Presenter: Stephanie Barnes, Scientist, NGS Assay Development, DNAe

• - Detection of Ultra-Low Frequency Mutations

- Date: November 15th, 2025, 9:15 AM - 10:15 AM EST
- Presenter: Jarrett Killpack, Future Applications Development Lead, DNAe

These presentations will not only highlight the technological advancements of the LiDia-SEQ™ platform but also its potential applications in oncology and infectious diseases, addressing the critical needs of global healthcare.

DNAe is capitalizing on its pioneering semiconductor sequencing technology, working towards rapid point-of-need diagnostics for various healthcare applications. Currently, the company’s focus is on developing tests for bloodstream infections and monitoring antimicrobial resistance, with additional tests for viral infections and cancer diagnostics in the pipeline.

Situated in London and Carlsbad, California, DNAe has earned the FDA’s “Breakthrough Device” designation for its innovative platform. The company is backed by the Biomedical Advanced Research and Development Authority (BARDA), emphasizing the importance of their work in combating antimicrobial-resistant infections.

For healthcare professionals, researchers, and anyone interested in the future of diagnostics, DNAe's presentation at AMP 2025 promises to deliver exciting insights into a rapidly evolving field designed to improve patient care and outcomes. To schedule a meeting with the DNAe team at AMP 2025, interested parties can reach out through the provided contact methods.

Follow DNAe for updates and insights into their ongoing developments and innovations in healthcare diagnostics.